Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 355-361

  Bonneterre, J ^a,b   Revillion F ^a   Desauw, C ^c   Blot, E ^d   Kramar, A ^a   Fournier, C ^a   Hornez, L ^a   Peyrat, J P ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CENTRE HENRI BECQUEREL   (France)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Proteomic analysis

Indexed keywords

C1 PROTEIN; C7 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; P1 PROTEIN; P7 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOSOL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PLASMA; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872851169     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2090     Document Type: Article

References (33)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003.
3. Roche H, Fumoleau P, Spielman M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24: 5664-5671, 2006.
4. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, et al: Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61: 76-80, 2001.
5. Adam BL, Qu Y, Davis JW, et al: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614, 2002.
6. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577, 2002 .
7. Petricoin EF III, Ornstein DK, Paweletz CP, et al: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94: 1576-1578, 2002.
8. Vlahou A, Laronga C, Wilson L, et al: A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 4: 203-209, 2003.
9. Koopmann J, Zhang Z, White N, et al: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10: 860-868, 2004.
10. Wadsworth JT, Somers KD, Cazares LH, et al: Serum protein profiles to identify head and neck cancer. Clin Cancer Res 10: 1625-1632, 2004.
11. Zhang Z, Bast RC Jr., Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882-5890, 2004.
12. Fung ET, Yip TT, Lomas L, et al: Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115: 783-789, 2005.
13. Fung ET, Thulasiraman V, Weinberger SR and Dalmasso EA: Protein biochips for differential profiling. Curr Opin Biotechnol 12: 65-69, 2001.
14. Hodgkinson VC, Eagle GL, Drew PJ, Lind MJ and Cawkwell L: Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett 294: 13-24, 2010.
15. He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF and Chang HR: Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol 35: 683-692, 2009.
16. Sataloff DM, Mason BA, Prestipino AJ, Seinige VL, Lieber CP and Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297-306, 1995.
17. Bradford MM: Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
18. Kramar A, Farraggi D, Fortuné A and Reiser B: mROC: a computer program for combining tumour markers in predicting disease states. Comput Methods Programs Biomed 66: 199-207, 2001.
19. Kozak KR, Amneus MW, Pusey SM, et al: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 100: 12343-12348, 2003.
20. Gonçalves A, Esterni B, Bertucci F, et al: Postoperative serum proteomic profiles may predict metastatic relapse in high-riskprimary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25: 981-989, 2006.
21. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96: 353-356, 2004.
22. Ricolleau G, Charbonnel C, Lodé L, et al: Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6: 1963-1975, 2006.
23. Pusztai L, Gregory BW, Baggerly KA, et al: Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814-1822, 2004.
24. Zhang K, Yuan K, Wu H, et al: Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS. Appl Biochem Biotechnol 166: 753-763, 2012.
25. Dang CT and Hudis C: Preoperative chemotherapy for operable breast cancer. In Diseases of the Breast. Harris JR, Lippman ME, Morrow M and Osborne CK (eds). WoltersKluwer/ Lippincott Williams &Williams, Philadelphia, pp715-723, 2010.
26. Mailliez A, Baranzelli MC, Giard S, et al: Is there a reliable method to assess the complete pathologic response on the tumor after neo-adjuvant chemotherapy in inflammatory breast cancer toward recommendations for the pathologic process? Experience in 56 patients treated in a single institution. Breast J 16: 464-471, 2010.
27. Penault-Llorca F, Abrial C, Raolelfils I, et al: Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 13: 1235-1245, 2008.
28. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
29. Katz A, Saad ED, Porter P and Pusztai L: Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 8: 55-62, 2007.
30. Liedtke C, Hatzis C, Symmans WF, et al: Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27: 3185-3191, 2009.
31. Straver ME, Glas AM, Hannemann J, et al: The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119: 551-558, 2010.
32. Tabchy A, Valero V, Vidaurre T, et al: Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16: 5351-5361, 2010.
33. Lee JK, Coutant C, Kim YC, et al: Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 16: 711-718, 2010.